Dexcel Pharma Executive and Leadership Team

Ilan Oren, the Co-Chief Executive Officer at Dexcel Pharma, directs the overarching corporate strategy and operational execution for Israel's largest privately owned pharmaceutical company. Overseeing global market expansion, Oren ensures Dexcel Pharma's value-added branded prescription drugs, generics, and OTC products reach key international territories including the U.S., U.K., and Germany. This leadership involves aligning subsidiary operations and distribution partner networks to maximize market penetration and revenue streams. By focusing on the development and commercialization of oral solid dosage forms, Oren drives innovation within the company's extensive product portfolio of over 85 distinct offerings. The Co-Chief Executive Officer's strategic vision guides Dexcel Pharma's continued growth and its commitment to delivering high-quality pharmaceutical solutions worldwide. Ilan Oren's leadership ensures sustained market leadership and operational excellence across all facets of the business.

Yaron Erez, the Chief Financial Officer & Vice President at Dexcel Pharma, manages the company's financial strategy and fiscal operations, ensuring robust economic health for Israel's largest privately owned pharmaceutical entity. Overseeing all financial planning, budgeting, and investment activities, Erez supports Dexcel Pharma's global commercialization efforts across markets such as the U.S. and U.K. This role is critical for funding the development and manufacturing of value-added branded prescription drugs, generics, and OTC products. By driving financial discipline and identifying strategic growth opportunities, the Chief Financial Officer & Vice President plays a key part in sustaining the company's expansion and profitability. Yaron Erez's financial acumen guides Dexcel Pharma's resource allocation and strengthens its position in the competitive international pharmaceutical landscape.

Ziv Teresh, the Chief Operating Officer & Vice President at Dexcel Pharma, directs the end-to-end operational framework supporting the company's diverse pharmaceutical product lines. Overseeing manufacturing processes, supply chain logistics, and quality control for oral solid dosage forms, Teresh ensures the consistent delivery of high-quality generics and branded prescription drugs. This leadership is vital for Dexcel Pharma's extensive market presence, including operations in Germany and Austria, and for managing relationships with distribution partners. By optimizing production efficiencies and maintaining rigorous compliance standards, the Chief Operating Officer & Vice President directly contributes to the company's ability to supply over 175 dosage forms globally. Ziv Teresh's operational expertise underpins Dexcel Pharma's reputation for reliability and its capacity for large-scale pharmaceutical manufacturing.

Miri Peleg, the Chief Information Officer & Vice President at Dexcel Pharma, architects the company's comprehensive digital infrastructure and information technology strategy. Overseeing all aspects of data management, cybersecurity, and technological innovation, Peleg ensures seamless integration of systems across Dexcel Pharma's development, manufacturing, and commercialization arms. This role is critical for supporting the company's extensive product lines, including generics and OTC offerings, and facilitating efficient operations in markets like the U.S. and U.K. By driving digital transformation initiatives, the Chief Information Officer & Vice President enhances operational efficiency and supports data-driven decision-making throughout the organization. Miri Peleg's leadership ensures that Dexcel Pharma leverages cutting-edge technology to maintain its competitive edge and uphold stringent quality standards in pharmaceutical production and distribution.

Esther Hagai, the Chief Medical Officer at Dexcel Pharma, leads the company's medical affairs and clinical development initiatives, ensuring the scientific integrity and efficacy of its pharmaceutical products. Overseeing clinical research, regulatory submissions, and medical communications, Hagai guides the strategic direction for Dexcel Pharma's branded prescription drugs and generics. This leadership is essential for navigating complex regulatory environments in key markets like the U.S. and Germany and for validating the value-added nature of the company's offerings. By fostering a deep understanding of therapeutic areas and patient needs, the Chief Medical Officer ensures that Dexcel Pharma's product pipeline aligns with global healthcare demands. Esther Hagai's medical expertise drives innovation and reinforces the company's commitment to advancing patient health through scientifically sound pharmaceutical solutions.